Company Reports / Gilead Sciences, Inc.
COMPANY: Gilead Sciences, Inc.
INDEX RANK: 8th
Total Impact Score: 642,317.01
Gilead Sciences, Inc. is ranked 8th place in our index for 2015. Gilead Sciences, Inc.’s drugs have a total impact score of 642,317.01. Gilead Sciences, Inc. treats one disease in our model - HIV - with two total drugs - Tenofovir (TDF) and Emtricitabine (FTC). Gilead Sciences, Inc. receives credit for two treatments against HIV - Tenofovir (TDF) and Emtricitabine (FTC). These two drugs averted 621,283.21 of the total DALYS for HIV, which is 24.25% of the worldwide DALYs that we estimate would have been lost due to HIV in 2015 in the absence of effective treatment. Gilead Sciences, Inc.’s drug portfolio placed it 2nd in terms of total averted DALYs for HIV.
Company Score Breakdown:
Emtricitabine (FTC) is an ARV drug recommended by the WHO in the treatment of HIV as a part of preferred first-line regimens for adults and adolescents, as part of an alternative first-line regimen for children, and in cases of HBV coinfection. Major toxicity concerns include lactic acidosis and neutropenia. It was first developed by scientists at Emory University and Gilead Sciences Inc paid $525 million for the royalties.
Tenofovir (TDF) is an ARV drug recommended by the WHO in the treatment of HIV as a part of preferred first-line regimens for adults and adolescents, as a part of alternative first-line regimens for children older than three years, and as part of the recommended regimen in cases of HBV coinfection. Major toxicity concerns include chronic kidney disease, lactic acidosis, and decreases in bone mineral density. Tenofovir was first patented by Gilead Sciences Inc.
Gilead Sciences, Inc. is a biotechnology company founded in 1987 by Michael Rourdan and headquartered in California that develops and sells pharmaceuticals. Currently, the company is highly invested in drugs for HIV/AIDS, respiratory conditions, cardiovascular ailments, and metabolic disorders. Gilead works to improve access to HIV medicine in low/middle income countries with tiered pricing schemes, voluntary licensing agreements, and financial support to HIV/AIDS programs in various countries. They are currently the top manufacturer of HIV drugs and are in the process of testing a possible cure to HIV. Some of their key products include Truvada®, Biktavy® and Atripla®. They have about 10,000 employees operating in over 30 countries, and in 2017 they reported a revenue of approximately $26.1 billion.